BACKGROUND: Transitional cell carcinoma (TCC) of the urinary bladder of dogs can be a difficult cancer to treat, and effective therapies are limited. Vinblastine has been used in humans with TCC and has potent anti-proliferative effects against canine TCC cells in vitro. OBJECTIVES: To determine the antitumor activity and toxicoses of vinblastine in dogs with urinary bladder TCC. ANIMALS: Animals selected were 28 privately owned dogs that presented to the Purdue University Veterinary Teaching Hospital (PUVTH) with measurable, histologically confirmed TCC. METHODS: Prospective clinical trial: The starting vinblastine dosage was 3.0 mg/m(2) i.v. every 2 weeks. Treatment continued until cancer progression or unacceptable toxicoses occurred. Complete evaluations (physical exam, complete blood count [CBC], serum biochemical profile, urinalysis, thoracic radiography, abdominal ultrasound [US]) were performed at 8-week intervals. Urinary tract US with bladder tumor mapping was performed monthly. Toxicoses were graded according to Veterinary Co-Operative Oncology Group (VCOG) criteria. RESULTS: Tumor responses included 10 (36%) partial remission, 14 (50%) stable disease, and 4 (14%) progressive disease. The median progression free interval was 122 days (range, 28-399 days). The median survival time was 147 days (range, 28-476 days) from 1st vinblastine treatment to death and 299 days (range, 43-921 days) from diagnosis to death. The majority of dogs (27 of 28) did not have clinically relevant adverse effects. Seventeen of 28 (61%) dogs required dosage reductions because of neutropenia. CONCLUSION AND CLINICAL IMPORTANCE: Vinblastine has antitumor activity against TCC in dogs and can be considered another treatment option for this cancer.
BACKGROUND: Transitional cell carcinoma (TCC) of the urinary bladder of dogs can be a difficult cancer to treat, and effective therapies are limited. Vinblastine has been used in humans with TCC and has potent anti-proliferative effects against canine TCC cells in vitro. OBJECTIVES: To determine the antitumor activity and toxicoses of vinblastine in dogs with urinary bladder TCC. ANIMALS: Animals selected were 28 privately owned dogs that presented to the Purdue University Veterinary Teaching Hospital (PUVTH) with measurable, histologically confirmed TCC. METHODS: Prospective clinical trial: The starting vinblastine dosage was 3.0 mg/m(2) i.v. every 2 weeks. Treatment continued until cancer progression or unacceptable toxicoses occurred. Complete evaluations (physical exam, complete blood count [CBC], serum biochemical profile, urinalysis, thoracic radiography, abdominal ultrasound [US]) were performed at 8-week intervals. Urinary tract US with bladder tumor mapping was performed monthly. Toxicoses were graded according to Veterinary Co-Operative Oncology Group (VCOG) criteria. RESULTS: Tumor responses included 10 (36%) partial remission, 14 (50%) stable disease, and 4 (14%) progressive disease. The median progression free interval was 122 days (range, 28-399 days). The median survival time was 147 days (range, 28-476 days) from 1st vinblastine treatment to death and 299 days (range, 43-921 days) from diagnosis to death. The majority of dogs (27 of 28) did not have clinically relevant adverse effects. Seventeen of 28 (61%) dogs required dosage reductions because of neutropenia. CONCLUSION AND CLINICAL IMPORTANCE: Vinblastine has antitumor activity against TCC in dogs and can be considered another treatment option for this cancer.
Authors: Marcus L Bradbury; Christine M Mullin; Shaban D Gillian; Chick Weisse; Philip J Bergman; Michelle A Morges; Lauren R May; David M Vail; Craig A Clifford Journal: Can Vet J Date: 2021-02 Impact factor: 1.008
Authors: Andrew J Leffler; Eric T Hostnik; Emma E Warry; Gregory G Habing; Danelle M Auld; Eric M Green; Wm Tod Drost Journal: Vet Radiol Ultrasound Date: 2018-07-10 Impact factor: 1.363
Authors: W T N Culp; C Weisse; A C Berent; J A Reetz; E L Krick; D E Jackson; P H Kass; C A Clifford; K U Sorenmo Journal: J Vet Intern Med Date: 2015-04-21 Impact factor: 3.333
Authors: Sarah B Rippy; Heather L Gardner; Sandra M Nguyen; Emma E Warry; Roberta A Portela; William Tod Drost; Eric T Hostnik; Eric M Green; Dennis J Chew; Juan Peng; Cheryl A London Journal: BMC Vet Res Date: 2016-11-17 Impact factor: 2.741
Authors: C J Henry; B K Flesner; S A Bechtel; J N Bryan; D J Tate; K A Selting; J C Lattimer; M E Bryan; L Grubb; F Hausheer Journal: J Vet Intern Med Date: 2017-10-27 Impact factor: 3.333
Authors: Christopher M Fulkerson; Deepika Dhawan; Timothy L Ratliff; Noah M Hahn; Deborah W Knapp Journal: Int J Genomics Date: 2017-04-09 Impact factor: 2.326
Authors: Deborah W Knapp; Audrey Ruple-Czerniak; José A Ramos-Vara; James F Naughton; Christopher M Fulkerson; Sonia I Honkisz Journal: Bladder Cancer Date: 2016-04-27